Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/21/24
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewsWire • 02/27/24
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®GlobeNewsWire • 12/05/23
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/23
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressGlobeNewsWire • 10/23/23
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersGlobeNewsWire • 10/17/23
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023GlobeNewsWire • 10/16/23
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersGlobeNewsWire • 09/28/23
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042GlobeNewsWire • 09/12/23
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/23
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerGlobeNewsWire • 08/03/23
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023GlobeNewsWire • 07/31/23
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual MeetingGlobeNewsWire • 05/25/23
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/23
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingGlobeNewsWire • 04/26/23
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/29/23
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical StudiesGlobeNewsWire • 03/29/23
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual MeetingGlobeNewsWire • 03/14/23
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 08/31/22